HC Wainwright Comments on Lineage Cell Therapeutics FY2026 Earnings

Lineage Cell Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright raised its FY2026 loss-per-share estimate for Lineage Cell Therapeutics to $0.01 from $0.08; its forecasts are a $0.02 loss per share for Q4 2026 and $0.07 losses per share in FY2027 and FY2028.
  • Lineage reported quarterly EPS of a $0.03 loss, matching analyst expectations, while revenue of $1.43 million fell short of the $2.32 million estimate.
  • Analyst sentiment remains broadly positive: MarketBeat rates the stock a “Moderate Buy,” with an average price target of $6.25. Shares opened at $0.80, near their 12-month low of $0.77.
  • Interested in Lineage Cell Therapeutics? Here are five stocks we like better.

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) - Stock analysts at HC Wainwright raised their FY2026 EPS estimates for shares of Lineage Cell Therapeutics in a report issued on Friday, November 13th. HC Wainwright analyst J. Pantginis now forecasts that the company will earn ($0.01) per share for the year, up from their previous estimate of ($0.08). The consensus estimate for Lineage Cell Therapeutics' current full-year earnings is ($0.07) per share. HC Wainwright also issued estimates for Lineage Cell Therapeutics' Q4 2026 earnings at ($0.02) EPS, FY2027 earnings at ($0.07) EPS and FY2028 earnings at ($0.07) EPS.

Separately, Raymond James Financial restated a "market perform" rating on shares of Lineage Cell Therapeutics in a report on Friday. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, Lineage Cell Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $6.25.

View Our Latest Stock Report on Lineage Cell Therapeutics

Lineage Cell Therapeutics Price Performance

Shares of NYSEAMERICAN:LCTX opened at $0.80 on Tuesday. The company's fifty day moving average is $0.99 and its two-hundred day moving average is $1.29. Lineage Cell Therapeutics has a 12-month low of $0.77 and a 12-month high of $1.99.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.03) EPS for the quarter, hitting analysts' consensus estimates of ($0.03). Lineage Cell Therapeutics had a net margin of 16.18% and a return on equity of 3.37%. The firm had revenue of $1.43 million during the quarter, compared to analyst estimates of $2.32 million.

Hedge Funds Weigh In On Lineage Cell Therapeutics

A number of large investors have recently made changes to their positions in LCTX. StoneX Group Inc. lifted its position in shares of Lineage Cell Therapeutics by 74.9% in the third quarter. StoneX Group Inc. now owns 29,747 shares of the company's stock worth $30,000 after purchasing an additional 12,739 shares in the last quarter. Equitable Holdings Inc. acquired a new stake in shares of Lineage Cell Therapeutics during the second quarter worth approximately $39,000. Two Sigma Securities LLC grew its position in Lineage Cell Therapeutics by 85.4% during the second quarter. Two Sigma Securities LLC now owns 37,793 shares of the company's stock valued at $50,000 after purchasing an additional 17,403 shares in the last quarter. State of Wyoming purchased a new position in Lineage Cell Therapeutics during the second quarter valued at approximately $57,000. Finally, Cibc World Market Inc. purchased a new position in Lineage Cell Therapeutics during the second quarter valued at approximately $62,000. Institutional investors and hedge funds own 62.47% of the company's stock.

Lineage Cell Therapeutics Company Profile

(Get Free Report)

Lineage Cell Therapeutics is a biotechnology company developing cell-based therapies for serious medical conditions. The company uses its cell therapy platform to create and manufacture specialized human cells intended to replace or support damaged cells and tissues. Its programs include OpRegen, a retinal pigment epithelial cell therapy being developed for retinal diseases; OPC1, an oligodendrocyte progenitor cell therapy for spinal cord injury; ANP1, an auditory neuron progenitor cell program for hearing loss; and VAC2, a cell-based cancer immunotherapy.

See Also

Earnings History and Estimates for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Lineage Cell Therapeutics Right Now?

Before you consider Lineage Cell Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lineage Cell Therapeutics wasn't on the list.

While Lineage Cell Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines